Jane Street’s VistaGen Therapeutics VTGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$156K Sell
272,811
-254,316
-48% -$155K ﹤0.01% 10356
2025
Q4
$349K Buy
527,127
+224,444
+74% +$811K ﹤0.01% 8489
2025
Q3
$1.07M Buy
302,683
+207,632
+218% +$620K ﹤0.01% 6160
2025
Q2
$190K Buy
+95,051
New +$216K ﹤0.01% 8589
2024
Q4
Sell
-19,659
Closed -$59.2K 10711
2024
Q3
$59.2K Buy
+19,659
New +$67.1K ﹤0.01% 9141
2024
Q1
Sell
-21,940
Closed -$113K 10170
2023
Q4
$113K Buy
+21,940
New +$83K ﹤0.01% 8531
2022
Q4
Sell
-2,272
Closed -$10K 10241
2022
Q3
$10K Buy
+2,272
New +$22.5K ﹤0.01% 9349
2022
Q2
Sell
-1,950
Closed -$73K 11013
2022
Q1
$73K Buy
+1,950
New +$85K ﹤0.01% 9569
2021
Q3
Sell
-5,522
Closed -$521K 10813
2021
Q2
$521K Buy
5,522
+4,858
+732% +$360K ﹤0.01% 7159
2021
Q1
$42K Buy
+664
New +$44.3K ﹤0.01% 8872
2020
Q3
Sell
-2,432
Closed -$38K 8000
2020
Q2
$38K Buy
+2,432
New +$33.3K ﹤0.01% 6902
2019
Q2
Sell
-745
Closed -$29K 5806
2019
Q1
$29K Buy
+745
New +$32.5K ﹤0.01% 4880

Other funds holding VTGN

Jane Street's VTGN Position: Q1 2026 in Review

Jane Street reduced its VistaGen Therapeutics (VTGN) stake by 48% in Q1 2026, selling an estimated $155K and leaving 272,811 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #10356.

Jane Street first reported a position in VTGN in Q1 2019 and has held it in 12 quarters since. The position peaked at $1.07M in Q3 2025. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Jane Street held 272,811 shares of VistaGen Therapeutics worth $156K as of Q1 2026.
  • Jane Street sold 254,316 VistaGen Therapeutics shares in Q1 2026, an estimated $155K.
  • VistaGen Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10356 holding.
  • Jane Street first reported a position in VistaGen Therapeutics in Q1 2019 and has held it in 12 quarters since.
  • Jane Street's VistaGen Therapeutics position peaked at $1.07M in Q3 2025.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.